EUCTR2018-000023-13-PL进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-LabelExtension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment ofChemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Sobi, Inc
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria will be eligible to participate in the study:
- •1. Subject is =18 years of age at the time of informed consent;
- •2. Subject with a diagnosis with ovarian cancer, lung cancer (small cell or non-small cell), or bladder cancer, requiring systemic chemotherapy;
- •3. Subject is currently receiving a chemotherapy regimen given in a 21-day or 28-day cycle (other chemotherapy cycle lengths are not allowed), including 1 or more of the following agents or class of agents:
- •-Nucleoside analog, including gemcitabine and fluorouracil;
- •-Carboplatin or cisplatin;
- •-Anthracycline; or
- •-Alkylating agent;
- •4. Subject experienced severe thrombocytopenia, defined as 2 platelet counts <50 × 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle (Cycle X), of their current chemotherapy regimen. Platelet counts obtained per standard of care during Cycle X prior to consent may be used;
- •5.Subject is planned to receive the same chemotherapy regimen and the same dose(s) on Chemotherapy Day (Days 1-3) of Cycle X+1 as was given in the qualifying chemotherapy Cycle X;
- •6. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status =2;
- •7. Subject has a life expectancy >12 weeks at Screening and is able to receive at least 2 additional cycles of the current chemotherapy regimen;
- •8. Females of childbearing potential must agree to use a highly effective method of contraception (eg, total abstinence; an intrauterine device; hormonal contraceptive given orally, by injection, or by implant; double barrier contraception (i.e., condom + diaphragm); or has a vasectomized
- •partner with confirmed azoospermia) throughout the entire study period and for 30 days after investigational product (IP) discontinuation. If currently abstinent, the subject must agree to use an effective method as described above if she becomes sexually active during the study period or for 30 days after IP discontinuation. Male subjects must be either surgically sterile or agree to use a double barrier contraception method (combination of male condom with either cap, diaphragm, or sponge with a spermicide) throughout the entire study period and for 30 days after IP discontinuation;
- •9. Subject is willing and able to comply with all aspects of the protocol; and
- •10. Subject must provide written informed consent.
- •Inclusion Criteria for Subjects to Continue Into the Optional Open-Label Extension Period
- •Subjects who meet all of the following criteria will be eligible to continue into the optional
- •Open-Label Extension (OLE) Period:
- •1. Subject is currently receiving the same chemotherapy agents as were given in the qualifying chemotherapy Cycle X;
- •2. Subject has an ECOG performance status =2;
- •3. Females of childbearing potential must agree to use a highly effective method of contraception as previously defined.
- •Male subjects must be either surgically sterile or agree to use a double barrier contraception method (combination of male condom with either cap, diaphragm, or sponge with a spermicide) throughout the entire study period and for 30 days after IP discontinuation;
- •4. Subject is willing and able to comply with all aspects of the protocol; and
- •5. Subject must provide consent to continue into the OLE Period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number o
排除标准
- •1. Subject has experienced = Grade 2 CIT with a platelet count <75 × 10^9/L (other than during the current chemotherapy treatment regimen) within 6 months of Screening;
- •2. Subject has a platelet count >175 × 10^9/L at Visit 2 (-1 day);
- •3. Subject with any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;
- •4. Subject who received >2 previous lines of chemotherapy (adjuvant/neoadjuvant therapy is considered a previous line; immunotherapy alone is not considered a previous line) or is receiving whole brain radiation during the study treatment period;
- •5. Subject with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 × upper limit of normal or total bilirubin =3 × upper limit of normal;
- •6. Subject has a known medical history of human immunodeficiency virus;
- •7. Subject has any known clinically significant acute or active bleeding (eg, gastrointestinal or central nervous system) within 7 days of Screening;
- •8. Subject has a known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden, prothrombin G20210A, or ATIII deficiency);
- •9. Subject has a recent history (within 3 months of Screening) of significant cardiovascular disease (eg, congestive heart failure exacerbation, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, or coronary artery bypass graft);
- •10. Subject has a history of arterial or venous thrombosis within 3 months of Screening;
- •11. Subject has used vitamin K antagonists within 7 days of Screening (use of low molecular weight heparin, Xa inhibitors, or thrombin inhibitors is allowed);
- •12. Subject has a history of chronic platelet or bleeding disorders or thrombocytopenia due to an etiology other than CIT (eg, chronic liver disease or immune thrombocytopenia purpura);
- •13. Subject has used moderate or strong inducers of cytochrome P450 (CYP)2C or CYP3A4/5 within 7 days of Screening;
- •14. Subject has received a thrombopoietin receptor agonist (eg, eltrombopag or romiplostim) or recombinant human thrombopoietin for the treatment of CIT within 3 months of Screening;
- •15. Subject received a platelet transfusion within 72 hours of randomization;
- •16. Subject is unable to take oral medication;
- •17. Subject has any history of a concomitant medical condition that, in the opinion of the Investigator, would compromise the subject’s ability to safely complete the study, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring intravenous antibiotics;
- •18. Female subjects who are lactating or pregnant at Screening or the Baseline Visit (as documented by a positive serum or urine beta-human chorionic gonadotropin [ß-hCG] test);
- •19. Subject has hypersensitivity to avatrombopag or any of its excipients; or
- •20. Subject is currently enrolled in another clinical study with any investigational drug or device within 30 days of Screening; however, participation in observational studies is permitted.
- •Exclusion Criteria for Subjects to Continue Into the Optional Open-Label Extension Period Subjects who meet any of the following criteria will be excluded from continuing into the optional OLE Period:
- •1. Subject has a platelet count >175 × 10^9/L on the scheduled first day of dosing of avatrombopag prior to chemotherapy;
- •2. Subject with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82